Ovagen (EDL)
EDL Tripeptide | Liver & GI Bioregulator
Community Research
Join others researching Ovagen — share findings, ask questions, and learn from real experiences
Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.
Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.
Molecular Data
EDLGlutamic Acid
Position 1
Aspartic Acid
Position 2
Leucine
Position 3
Research Indications
Reduces long-term fibrosis development in liver tissue.
Protects liver through gene expression regulation.
Helps protect GI mucosal layer from various insults.
May protect GI tract from antibiotic-induced damage.
Protects against environmental toxin effects on GI tract.
Addresses age-related liver changes through bioregulation.
Supports GI tract function during aging.
Dosing Protocols
Available in capsule form for oral administration. As a tripeptide, Ovagen is transported via PEPT1/PEPT2 transporters for targeted delivery to liver and GI tissue. Typical protocol involves 10-20 day cycles.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | Oral capsules |
| Maintenance | 10 mg | 2-3 cycles yearly | Oral capsules |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Stop Signs - Discontinue if:
- Allergic reactions
- Unusual GI or liver symptoms
Contraindications
- Active liver emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
Quality Checklist
Good Signs
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Warning Signs
- Unknown source or purity
- Do not confuse with FSH derivative of same name
Bad Signs
- Discoloration
- Unusual odor
- Damaged packaging
References
- Khavinson Peptide Bioregulators OverviewAdvances in Gerontology (2020)
Ovagen (EDL) is a tripeptide bioregulator with effects on liver and GI tract.
- POT Family Transporters and Peptide BioregulatorsDrug Metabolism Reviews (2018)
Di- and tripeptides are transported via PEPT1/PEPT2, explaining tissue-specific targeting.
- Peptide Bioregulators and Liver FibrosisExperimental Gerontology (2019)
Short peptides reduce long-term fibrosis in liver tissue through gene expression regulation.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.